Malvern Panalytical acquires Creoptix

The company aims to expands its capabilities for drug development

165
Malvern Panalytical expands its pharmaceutical drug development solutions with the acquisition of Creoptix Photo Credit: Unsplash
Malvern Panalytical expands its pharmaceutical drug development solutions with the acquisition of Creoptix Photo Credit: Unsplash

Malvern Panalytical, a company that provides advanced analysis and services solutions for the pharma drug product development and services and solutions for other industries, has announced its acquisition of Creoptix, a specialist bioanalysis sensor company. The acquisition forms a critical part of Malvern Panalytical’s strategy to expand its capabilities in support of drug discovery.

Creoptix provides cutting-edge tools for molecular interaction analysis. Engineered around their proprietary Grating-Coupled Interferometry (GCI) technology, these tools enable researchers to access high-quality binding affinity and kinetics data across a broader range of samples than traditional SPR-based solutions, accelerating the discovery and development of new drug substances.

Creoptix’s technology to help Malvern Panalytical with better drug discovery

“We are really excited to be bringing the Creoptix team into the Malvern Panalytical family,” stated Mark Fleiner, President of Malvern Panalytical. “We have always been driven by our desire to support our customers in developing ground-breaking new drug products. Creoptix significantly builds on the instrumentation and services capabilities, and we have to achieve this, strengthening our position in supporting small molecule pharmaceutical development while also significantly growing our capabilities in the fast-growing biopharmaceutical space.”

Engineered around their proprietary Grating-Coupled Interferometry (GCI) technology, these tools enable researchers to access high-quality binding affinity and kinetics data across a broader range of samples than traditional SPR-based solutions, accelerating the discovery and development of new drug substances.

Line Stigen Raquet, chief executive officer at Creoptix, also sees significant opportunities resulting from joining the Malvern Panalytical team. “The purpose of Creoptix has always been to enable life scientists to accelerate drug discovery,” said Line. “Our Wave portfolio is designed with the vision to advance breakthrough science and to help scientists develop new and better drugs faster. We believe that this merger is an exciting opportunity to accelerate further and deliver on our purpose, as we benefit from the exceptional knowledge and global customer reach provided by Malvern Panalytical.”

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here